21.71
-0.28 (-1.27%)
| Previous Close | 21.99 |
| Open | 21.63 |
| Volume | 109,173 |
| Avg. Volume (3M) | 645,979 |
| Market Cap | 1,398,382,336 |
| Price / Sales | 19.79 |
| Price / Book | 3.43 |
| 52 Weeks Range | |
| Earnings Date | 14 Oct 2024 - 18 Oct 2024 |
| Operating Margin (TTM) | -433.83% |
| Diluted EPS (TTM) | -2.90 |
| Quarterly Revenue Growth (YOY) | -31.80% |
| Total Debt/Equity (MRQ) | 7.20% |
| Current Ratio (MRQ) | 5.28 |
| Operating Cash Flow (TTM) | -97.14 M |
| Levered Free Cash Flow (TTM) | -56.77 M |
| Return on Assets (TTM) | -29.46% |
| Return on Equity (TTM) | -57.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Nurix Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -3.0 |
| Price Volatility | 1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.80 |
|
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.45% |
| % Held by Institutions | 97.78% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 35.00 (BTIG, 61.22%) | Buy |
| 35.00 (HC Wainwright & Co., 61.22%) | Buy | |
| 35.00 (BMO Capital, 61.22%) | Buy | |
| 35.00 (UBS, 61.22%) | Buy | |
| Median | 35.00 (61.22%) | |
| Low | 29.00 (Needham, 33.58%) | Buy |
| Average | 33.80 (55.69%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 22.40 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 11 Dec 2024 | 35.00 (61.22%) | Buy | 21.31 |
| 21 Oct 2024 | 30.00 (38.19%) | Buy | 25.48 | |
| BTIG | 10 Dec 2024 | 35.00 (61.22%) | Buy | 22.06 |
| Needham | 10 Dec 2024 | 29.00 (33.58%) | Buy | 22.06 |
| 06 Nov 2024 | 29.00 (33.58%) | Buy | 27.00 | |
| BMO Capital | 06 Dec 2024 | 35.00 (61.22%) | Buy | 21.37 |
| UBS | 24 Oct 2024 | 35.00 (61.22%) | Buy | 25.22 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| RING CHRISTINE | - | 19.51 | -5,760 | -112,378 |
| Aggregate Net Quantity | -5,760 | |||
| Aggregate Net Value ($) | -112,378 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 19.51 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| RING CHRISTINE | Officer | 02 Jan 2025 | Automatic sell (-) | 5,760 | 19.51 | 112,378 |
| RING CHRISTINE | Officer | 02 Jan 2025 | Option execute | 5,760 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |